Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
4.526
Zitationen
20
Autoren
2012
Jahr
Abstract
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIRM ClinicalTrials.gov number, NCT00974311.).
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.691 Zit.
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 · 5.435 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.482 Zit.
Abiraterone and Increased Survival in Metastatic Prostate Cancer
2011 · 4.355 Zit.
Screening and Prostate-Cancer Mortality in a Randomized European Study
2009 · 3.986 Zit.
Autoren
Institutionen
- Memorial Sloan Kettering Cancer Center(US)
- Cornell University(US)
- Institut Gustave Roussy(FR)
- Université Paris-Sud(FR)
- Université de Montréal(CA)
- Dana-Farber Cancer Institute(US)
- Nini Hospital(LB)
- Charité - Universitätsmedizin Berlin(DE)
- Erasmus MC(NL)
- Radboud University Medical Center(NL)
- University Medical Center(US)
- Radboud University Nijmegen(NL)
- BC Cancer Agency(CA)
- Carolina Urologic Research Center(US)
- Duke Medical Center(US)
- University of Colorado Cancer Center(US)
- University of Colorado Denver(US)
- Centre Léon Bérard(FR)
- Mater Private Hospital(AU)
- Virginia Oncology Associates(US)
- Sarah Cannon(US)
- Sarah Cannon Research Institute(GB)
- Royal Marsden Hospital(GB)